Equillium, Inc. (NASDAQ: EQ) is a Healthcare company (Biotechnology) with a market capitalization of $100M. The Maz Rating grades it against the other companies in its sector.
Equillium, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.21, Equillium, Inc. trades at 2.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -37.3%, return on invested capital of -37.0% and a free cash flow yield of -15.7%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 19.49. Over the past 52 weeks the share price ranged from $0.81 to $3.54, with a beta of 2.04.
Equillium, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 11 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Equillium, Inc. (EQ) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 27.6% / 30% · Interest income / Revenue 49000000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 27.6% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 49000000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 27.6% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 49000000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.95% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.5% / 33.33% · Receivables / Avg Assets (4Q) 0.05% / 33.33% · Interest income / Revenue 49000000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 95.5% / 33.33% · (Cash+Recv) / Total Assets 95.5% / 33.33% · Interest income / Revenue 49000000.0% / 5% | Fail |
No. As of September 2026, Equillium, Inc. (EQ) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Equillium, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 49000000.0% of each dividend: Equillium, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.